The Psychometric Performance of the Kansas City Cardiomyopathy Questionnaire-12 in Symptomatic Obstructive Hypertrophic Cardiomyopathy.

BACKGROUND

A primary goal of treating patients with obstructive hypertrophic cardiomyopathy (oHCM) is to improve their symptoms, function, and quality of life. While the psychometric properties of the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ-23) have been described in oHCM, they have not been assessed for the shorter 12-item version (KCCQ-12), which is increasingly used in clinical practice.

METHODS AND RESULTS

Using data from the EXPLORER-HCM trial, the psychometric properties of the KCCQ-12 were evaluated. The KCCQ-12 domain and summary scores had moderate correlations with the most relevant clinical (New York Heart Association class, exercise duration, peak oxygen consumption) and patient-reported measures (EQ-5D-5L visual analog scale, Work Productivity and Activity Impairment [WPAI] questionnaire, and Hypertrophic Cardiomyopathy Symptom Questionnaire [HCMSQ]). KCCQ-12 domain scores had strong internal consistency and test-retest reliability, demonstrated significant and proportional changes with different magnitudes of clinical change (assessed with the patient global impression of change and patient impression of severity), and demonstrated close equivalence to the KCCQ-23 scores.

CONCLUSIONS

The KCCQ-12 demonstrated good psychometric performance for patients with oHCM, comparable to that of the KCCQ-23, supporting its use in clinical practice to care for patients with oHCM.

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest Dr Sauer discloses receiving research funding and/or honoraria for consultative services from Abbott, Acorai, Amgen, Astra Zeneca, Bayer, Biotronik, Boston Scientific, CSL Vifor, General Prognostics, Impulse Dynamics, Medtronic, Story Health, and owning stock in ISHI. Dr Sherrod is supported by NHLBI award T32HL110837. Dr Reaney is an employee and stockholder at IQVIA – a medical research organization which received funding from Bristol Myers Squibb for research in the EXPLORER-HCM program. Dr Zhong and Dr Wyrwich are employees of Bristol Myers Squibb and report stock or stock options. Jenny Lam was an employee of Bristol Myers Squibb when this work was conducted. Dr Spertus discloses providing consultative services on patient-reported outcomes and evidence evaluation to 4DT Medical, Abbott, Alnylam, AstraZeneca, Bayer, Bristol Myers Squibb, Cytokinetics, Edwards, Imbria, Janssen, Kiniksa, Merck, Terumo, and United Healthcare. He holds research grants from Abbott Vascular, Bristol Myers Squibb, and Janssen. He owns the copyright to the Kansas City Cardiomyopathy Questionnaire, the Peripheral Artery Questionnaire, and the Seattle Angina Questionnaire and serves on the Board of Directors for Blue Cross Blue Shield of Kansas City. The remaining authors report no disclosures.